U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    47,392.95
    -855.23 (-1.77%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Why Liquidia's Stock Is Trading Higher Today

  • Oops!
    Something went wrong.
    Please try again later.
Tanzeel Akhtar
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Liquidia (NASDAQ: LQDA) shares are trading higher on Monday. The company said that on Oct. 16 it had received an unsolicited offer to enter into a License Agreement for the LIQ861 and has postponed its special meeting in order to fully consider the offer.

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain.

Liquidia shares traded up 17.83% to $3.37 on Monday. The stock has a 52-week high of $12.10 and a 52-week low of $2.65.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.